A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism
Latest Information Update: 19 Mar 2025
At a glance
- Drugs SHR 6508 (Primary)
- Indications Secondary hyperparathyroidism
- Focus Pharmacokinetics
- Sponsors Shanghai Hengrui Pharmaceutical
- 19 Mar 2025 New trial record